

ATSDR MINIMAL RISK LEVELS (MRLs) FOR HAZARDOUS SUBSTANCES—Continued  
[March 1996]

Substance name	CAS No.	Route	Duration	Value	Factors	End point
1,3-DI-CHLORO-PROPENE.	000542-75-6	INHALATION .....	INTERMEDIATE .....	0.003 ppm .....	100	Respiratory.
		INHALATION .....	CHRONIC .....	0.002 ppm .....	100	Respiratory.
1,3-DI-NITRO-BENZENE	000099-65-0	ORAL .....	ACUTE .....	0.008 mg/kg/day .....	100	Reproductive.
		ORAL .....	INTERMEDIATE .....	0.0005 mg/kg/day .....	1000	Hematological.
1,4-DI-CHLORO-BENZENE.	000106-46-7	INHALATION .....	INTERMEDIATE .....	0.2 ppm .....	100	Hepatic.
		ORAL .....	INTERMEDIATE .....	0.1 mg/kg/day .....	100	Hepatic.
1-METHYLNAPHTHALENE.	000090-12-0	ORAL .....	CHRONIC .....	0.07 mg/kg/day .....	1000	Respiratory.
2,3,4,7,8-PENTACHLORO-DI-BENZOFURAN.	057117-31-4	ORAL .....	ACUTE .....	0.000001 mg/kg/day	3000	Immunological.
		ORAL .....	INTERMEDIATE .....	0.00000003 mg/kg/day.	3000	Hepatic.
2,3,7,8-TETRACHLORO-DIBENZOP-DIOXIN.	001746-01-6	ORAL .....	ACUTE .....	0.0000001 mg/kg/day	1000	Hepatic.
		ORAL .....	INTERMEDIATE .....	0.000000001 mg/kg/day.	1000	Reproductive.
		ORAL .....	CHRONIC .....	0.000000001 mg/kg/day.	1000	Reproductive.
2,4,6-TRI-CHLOROPHENOL.	000088-06-2	ORAL .....	INTERMEDIATE .....	0.04 mg/kg/day .....	100	Reproductive.
2,4,6-TRI-NITROTOLUENE.	000118-96-7	ORAL .....	INTERMEDIATE .....	0.0005 mg/kg/day .....	1000	Hepatic.
2,4-DI-NITRO-PHENOL	000051-28-5	ORAL .....	ACUTE .....	0.01 mg/kg/day .....	100	Body Weight.
2,4-DI-NITRO-TOLUENE	000121-14-2	ORAL .....	ACUTE .....	0.06 mg/kg/day .....	1000	Hematological.
		ORAL .....	INTERMEDIATE .....	0.05 mg/kg/day .....	100	Reproductive.
		ORAL .....	CHRONIC .....	0.002 mg/kg/day .....	100	Hematological.
		ORAL .....	INTERMEDIATE .....	0.04 mg/kg/day .....	100	Neurological.
4,4°-METHYL-ENE-BIS (2-CHLOROANILINE).	000101-14-4	ORAL .....	CHRONIC .....	0.003 mg/kg/day .....	3000	Hepatic.
4,6-DI-NITRO-O-CRESOL.	000534-52-1	ORAL .....	ACUTE .....	0.004 mg/kg/day .....	100	Neurological.
		ORAL .....	INTERMEDIATE .....	0.004 mg/kg/day .....	100	Neurological.

[FR Doc. 96-12991 Filed 5-22-96; 8:45 am]  
BILLING CODE 4163-70-P

**Food and Drug Administration**

**Advisory Committee; Science Board to the Food and Drug Administration; Formation of a Subcommittee**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the formation of a subcommittee of the Science Board to the Food and Drug Administration (Science Board). This subcommittee has been established to address issues related to science and research in FDA. The subcommittee's preliminary recommendations will be presented to the FDA Science Board for full public discussion at a future Science Board meeting.

**FOR FURTHER INFORMATION CONTACT:** Susan A. Homire, Office of Science (HF-33), Food and Drug

Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-3340.

**SUPPLEMENTARY INFORMATION:** The Food and Drug Administration (FDA) is announcing the formation of a subcommittee to the Science Board to the Food and Drug Administration. This subcommittee has been established to address issues related to science and research in FDA. The subcommittee will meet several times over the next 6 to 9 months to develop preliminary recommendations for the Science Board on a process for review of research programs within FDA. During this period there will be opportunities for public comment; these opportunities will be announced in the Federal Register at least 15 days prior to each scheduled public meeting. The subcommittee's preliminary recommendations will be presented to the Science Board for full public discussion at a future Science Board meeting. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92-463 (5 U.S.C. app. 2)).

Dated: May 16, 1996.  
Michael A. Friedman,  
*Deputy Commissioner for Operations.*  
[FR Doc. 96-12877 Filed 5-22-96; 8:45 am]  
BILLING CODE 4160-01-F

**Investigational Biological Product Trials; Procedure to Monitor Clinical Hold Process; Meeting of Review Committee and Request for Submissions**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing a meeting of the clinical hold review committee, which reviews the clinical hold orders that the Center for Biologics Evaluation and Research (CBER) has placed on certain investigational biological product trials. FDA is inviting any interested biological product company to use this confidential mechanism to submit to the committee for its review the name and number of